Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and will enroll up to 39 participants. Patients will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, a strategy that leverages Lantern's proprietary RADR platform to identify those most likely to benefit from the therapy.
The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies. This represents a significant step for Lantern Pharma, as it expands the clinical development of LP-184 into a new indication beyond its ongoing programs in pediatric CNS cancers and other solid tumors. The EMA clearance facilitates European enrollment and underscores the potential of LP-184 as a targeted therapy for bladder cancer, a disease with limited treatment options after progression on first-line therapies.
This announcement is important because it validates Lantern's AI-driven precision oncology approach. By using biomarkers to select patients, the trial aims to improve response rates and reduce unnecessary exposure to ineffective treatments. If successful, LP-184 could offer a new therapeutic option for bladder cancer patients with specific molecular profiles, addressing an unmet medical need. The study also advances Lantern's broader strategy of developing genomically targeted therapies, as highlighted in the full press release available at https://ibn.fm/6ku4F.
Lantern Pharma's pipeline includes other candidates such as LP-284 for hematologic and solid tumors and LP-300 for lung adenocarcinoma, the latter being evaluated in the HARMONIC Phase 2 trial. The company's RADR platform and its commercially available multi-agentic AI co-scientist platform, withZeta.ai, represent additional assets that could drive future growth. The EMA clearance for LP-184 marks a key milestone in expanding the clinical utility of Lantern's precision oncology portfolio, with implications for patients and investors alike.
